{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:03:04Z","timestamp":1794423784184,"version":"4.9.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jhep.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T22:28:56Z","timestamp":1702506536000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2464","authenticated-orcid":false,"given":"Terry Cheuk-Fung","family":"Yip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-1598","authenticated-orcid":false,"given":"Jimmy Che-To","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz-Fai","family":"Yam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Kit","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki Wing-Ki","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy Sze-Man","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-1611","authenticated-orcid":false,"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-9410","authenticated-orcid":false,"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-9389","authenticated-orcid":false,"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.12.001_bib1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/apt.14497","article-title":"Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B","volume":"47","author":"Wong","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.12.001_bib2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.27894","article-title":"Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects","volume":"62","author":"Wong","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.12.001_bib3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/apt.14945","article-title":"Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment","volume":"48","author":"Wong","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.12.001_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cgh.2014.09.050","article-title":"Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B","volume":"13","author":"Wong","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.12.001_bib5","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jhep.2015.06.025","article-title":"Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B","volume":"63","author":"Chan","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.12.001_bib6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/hep.30833","article-title":"An aging population of chronic hepatitis B with increasing comorbidities: a territory-wide study from 2000 to 2017","volume":"71","author":"Wong","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.12.001_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.13659","article-title":"Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients","volume":"44","author":"Lampertico","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.12.001_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.12.001_bib9","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.12.001_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2023.12.001_bib11","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/jmv.27863","article-title":"Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate","volume":"94","author":"Liang","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2023.12.001_bib12","article-title":"Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety","author":"Chan","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.12.001_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1076739","article-title":"Changes in bone quality after switching from a TDF to a TAF based ART: a pilot randomized study","volume":"14","author":"Soldado-Folgado","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jhep.2023.12.001_bib14","first-page":"1468","article-title":"Development journey of clinical data analysis and reporting system (CDARS) in hospital authority of Hong Kong","author":"Cheng","year":"2010","journal-title":"MEDINFO"},{"key":"10.1016\/j.jhep.2023.12.001_bib15","unstructured":"The Hospital Authority. Hospital authority statistical report 2021\u20132022. https:\/\/www3.ha.org.hk\/data\/HAStatistics\/DownloadReport\/14?isPreview=False (Accessed 25 August 2023)."},{"key":"10.1016\/j.jhep.2023.12.001_bib16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2019.12.005","article-title":"Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B","volume":"72","author":"Yip","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.12.001_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.12.001_bib18","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1111\/jgh.15664","article-title":"Secular trend of treatment uptake in patients with chronic hepatitis B: a territory-wide study of 135 395 patients from 2000 to 2017","volume":"36","author":"Lai","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.12.001_bib19","article-title":"Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis","volume":"5","author":"Hui","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.12.001_bib20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/apt.14341","article-title":"Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.12.001_bib21","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2023.12.001_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jclinepi.2019.02.016","article-title":"The proportion of missing data should not be used to guide decisions on multiple imputation","volume":"110","author":"Madley-Dowd","year":"2019","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jhep.2023.12.001_bib23","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2023.12.001_bib24","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures\u00a0can be a useful diagnostic for propensity score methods in\u00a0comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jhep.2023.12.001_bib25","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2023.12.001_bib26","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2023.12.001_bib27","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/sim.3618","article-title":"Imputing missing covariate values for the Cox model","volume":"28","author":"White","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2023.12.001_bib28","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1002\/sim.5815","article-title":"Goodness-of-fit test for proportional subdistribution hazards model","volume":"32","author":"Zhou","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2023.12.001_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/sim.8399","article-title":"A\u00a0review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model","volume":"39","author":"Austin","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2023.12.001_bib30","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2023.12.001_bib31","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2023.12.001_bib32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/14740338.2022.2045271","article-title":"Safety of current antiviral drugs for chronic hepatitis B","volume":"21","author":"Masetti","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jhep.2023.12.001_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008760","article-title":"Pathologic femoral fracture due to tenofovir-induced Fanconi syndrome in patient with chronic hepatitis B: a case report","volume":"96","author":"Suh","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2023.12.001_bib34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"Grant","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jhep.2023.12.001_bib35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12072-021-10148-z","article-title":"A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2023.12.001_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate","volume":"20","author":"Byun","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.12.001_bib37","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2023.12.001_bib38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/toxsci\/kfw208","article-title":"Editor\u2019s highlight: comparative renal safety assessment of the hepatitis B drugs, adefovir, tenofovir, telbivudine and entecavir in rats","volume":"vol. 155","author":"Uteng","year":"2017","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jhep.2023.12.001_bib39","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2023.12.001_bib40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.12.001_bib41","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0168-8278(17)30312-4","article-title":"PS-041 - improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B","volume":"66","author":"Chan","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.12.001_bib42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/apt.17107","article-title":"Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study","volume":"56","author":"Ogawa","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.12.001_bib43","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/apt.17716","article-title":"Tenofovir disoproxil fumarate vs. tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: a nationwide claims study in South Korea","volume":"58","author":"Kim","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.12.001_bib44","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.3390\/ijms20194873","article-title":"Impact of diabetes mellitus on bone health","volume":"20","author":"Murray","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2023.12.001_bib45","first-page":"169","article-title":"Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism","volume":"13","author":"Cappuccio","year":"2000","journal-title":"J Nephrol"},{"key":"10.1016\/j.jhep.2023.12.001_bib46","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1161\/CIRCULATIONAHA.108.784009","article-title":"Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients","volume":"118","author":"van Diepen","year":"2008","journal-title":"Circulation"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823053540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823053540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:58:53Z","timestamp":1773457133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823053540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0168827823053540"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.12.001","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}